Skip to content

SABS

SAB Biotherapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.11
−0.48%
Ask drillr

Forward multiples

Based on analyst estimates

P/E forward
—
P/E 2026E
—
P/E 2027E
—
P/E 2028E
—
P/S forward
2260.10x

Trailing multiples

Trailing twelve months

P/E TTM
0.87x
PEG TTM
—
Price / book
1.32x
Price / sales
—
Price / cash flow
-4.14x

Enterprise value

Enterprise value
$185.0M
EV / sales
—
EV / EBITDA
-19.62x
EV / EBIT
-2.58x
Market cap
$282.5M

Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026